Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

by Perkovic, Vlado , Jardine, Meg J , Cannon, Christopher P , Pollock, Carol , Charytan, David M , Greene, Tom , Neal, Bruce , Zhang, Hong , Mahaffey, Kenneth W , Bull, Scott , Meininger, Gary , Bakris, George , Levin, Adeera , de Zeeuw, Dick , Yavin, Yshai , Capuano, George , Bompoint, Severine , Heerspink, Hiddo J.L , Chu, Pei-Ling , Wheeler, David C , Brenner, Barry M , Agarwal, Rajiv , Edwards, Robert , Zinman, Bernard

in Aged / Amputation / Angiotensin / Antidiabetics / Canagliflozin - adverse effects / Canagliflozin - therapeutic use / Cardiovascular diseases / Cardiovascular Diseases - epidemiology / Cardiovascular Diseases - mortality / Cardiovascular Diseases - prevention & control / Cerebral infarction / Clinical outcomes / Clinical trials / Collaboration / Creatinine / Creatinine - blood / Death / Diabetes / Diabetes mellitus / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - blood / Diabetes Mellitus, Type 2 - complications / Diabetes Mellitus, Type 2 - drug therapy / Diabetic Nephropathies - complications / Diabetic Nephropathies - drug therapy / Dialysis / Double-Blind Method / End-stage renal disease / Enzymes / Female / Follow-Up Studies / Glomerular Filtration Rate / Heart diseases / Hemodialysis / Humans / Immunosuppressive agents / Kidney diseases / Kidney Failure, Chronic - epidemiology / Kidney Failure, Chronic - prevention & control / Kidney transplantation / Laboratories / Male / Middle Aged / Myocardial infarction / Nephropathy / Renal failure / Renin / Sodium / Sodium-glucose cotransporter / Sodium-Glucose Transporter 2 Inhibitors - adverse effects / Sodium-Glucose Transporter 2 Inhibitors - therapeutic use

2019

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

2019

Confirm

Do you wish to request the book?

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

2019

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, Vlado,

Jardine, Meg J,

Cannon, Christopher P,

Pollock, Carol,

Charytan, David M,

Greene, Tom,

Neal, Bruce,

Zhang, Hong,

Mahaffey, Kenneth W,

Bull, Scott,

Meininger, Gary,

Bakris, George,

Levin, Adeera,

de Zeeuw, Dick,

Yavin, Yshai,

Capuano, George,

Bompoint, Severine,

Heerspink, Hiddo J.L,

Chu, Pei-Ling,

Wheeler, David C,

Brenner, Barry M,

Agarwal, Rajiv,

Edwards, Robert,

Zinman, Bernard

2019

Overview

This double-blind, randomized trial compared canagliflozin with placebo in patients with type 2 diabetes and evidence of kidney disease that was treated with renin–angiotensin system blockade. The canagliflozin group had a lower risk of kidney disease progression or cardiovascular events than the placebo group.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

/ Canagliflozin - adverse effects

/ Canagliflozin - therapeutic use

/ Cardiovascular diseases